Targeting the Ras-ERK pathway in pancreatic adenocarcinoma

Cancer and Metastasis Reviews

Volumn 32, Issue 1-2, 2013, Pages 147-162

  Neuzillet, Cindy ^a   Hammel, Pascal ^a   Tijeras Raballand, Annemilaï ^b   Couvelard, Anne ^c   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b AAREC Filia Research   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

EMT; ERK; MAP kinases; MEK inhibitors; Pancreatic adenocarcinoma; Pancreatic cancer; Resistance; Targeted therapies

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BEVACIZUMAB; BRCA2 PROTEIN; CETUXIMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; ERLOTINIB; GEMCITABINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NERVE CELL ADHESION MOLECULE; PEPTIDE VACCINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN; SORAFENIB; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VIMENTIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DNA METHYLATION; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RASH; RETINA VEIN OCCLUSION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VISUAL DISORDER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84878115447     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9396-2     Document Type: Review

References (100)

1. Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60(5), 277-300. doi: 10.3322/caac.20073.
2. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. doi: 10.1002/ijc.25516.
3. Hidalgo, M. (2010). Pancreatic cancer. The New England Journal of Medicine, 362(17), 1605-1617. doi: 10.1056/NEJMra0901557.
4. Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011). Pancreatic cancer. Lancet, 378(9791), 607-620. doi: 10.1016/S0140- 6736(10)62307-0.
5. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15(6), 2403-2413.
6. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25(15), 1960-1966. doi: 10.1200/JCO.2006.07.9525.
7. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine, 364(19), 1817-1825. doi: 10.1056/NEJMoa1011923.
8. McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., Chang, F., et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta, 1773(8), 1263-1284. doi: 10.1016/j.bbamcr.2006.10.001.
9. Preis, M., & Korc, M. (2010). Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biology & Therapy, 9(10), 754-763.
10. Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, S. (2007). Ras oncogenes and their downstream targets. Biochimica et Biophysica Acta, 1773(8), 1177-1195. doi: 10.1016/j.bbamcr.2007.01.012.
11. Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., et al. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2(3), 135-164.
12. Ramos, J. W. (2008). The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. The International Journal of Biochemistry & Cell Biology, 40(12), 2707-2719. doi: 10.1016/j.biocel.2008.04.009.
13. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968-972. doi: 10.1038/nature09627.
14. Coles, L. C., & Shaw, P. E. (2002). PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene, 21(14), 2236-2244. doi: 10.1038/sj.onc.1205302.
15. Schafer, R., & Sers, C. (2011). RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function. Advances in Enzyme Regulation, 51(1), 126-136. doi: 10.1016/j.advenzreg.2010.11.005.
16. Owens, D. M., & Keyse, S. M. (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene, 26(22), 3203-3213. doi: 10.1038/sj.onc.1210412.
17. Calvo, F., Agudo-Ibanez, L., & Crespo, P. (2010). The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays, 32(5), 412-421. doi: 10.1002/bies.200900155.
18. Roberts, P. J., & Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26(22), 3291-3310. doi: 10.1038/sj.onc.1210422.
19. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. doi: 10.1016/j.cell.2011.02.013.
20. Roovers, K., & Assoian, R. K. (2000). Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays, 22(9), 818-826. doi: 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6.
21. Mirza, A. M., Gysin, S., Malek, N., Nakayama, K., Roberts, J. M., & McMahon, M. (2004). Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Molecular and Cellular Biology, 24(24), 10868-10881. doi: 10.1128/MCB.24.24.10868-10881.2004.
22. Maurer, G., Tarkowski, B., & Baccarini, M. (2011). Raf kinases in cancer - roles and therapeutic opportunities. Oncogene, 30(32), 3477-3488. doi: 10.1038/onc.2011.160 onc2011160.
23. Wang, S., Ghosh, R. N., & Chellappan, S. P. (1998). Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Molecular and Cellular Biology, 18(12), 7487-7498.
24. Ballif, B. A., & Blenis, J. (2001). Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth & Differentiation, 12(8), 397-408.
25. Balmanno, K., & Cook, S. J. (2009). Tumour cell survival signalling by the ERK1/2 pathway. Cell Death and Differentiation, 16(3), 368-377. doi: 10.1038/cdd.2008.148.
26. Allan, L. A., Morrice, N., Brady, S., Magee, G., Pathak, S., & Clarke, P. R. (2003). Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nature Cell Biology, 5(7), 647-654. doi: 10.1038/ncb1005 ncb1005.
27. Sahu, R. P., Batra, S., Kandala, P. K., Brown, T. L., & Srivastava, S. K. (2011). The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 67(2), 481-487. doi: 10.1007/s00280-010-1463-1.
28. Maida, Y., Kyo, S., Kanaya, T., Wang, Z., Yatabe, N., Tanaka, M., et al. (2002). Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene, 21(26), 4071-4079. doi: 10.1038/sj.onc.1205509.
29. Ellenrieder, V., Hendler, S. F., Boeck, W., Seufferlein, T., Menke, A., Ruhland, C., et al. (2001). Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Research, 61(10), 4222-4228.
30. Cano, C. E., Motoo, Y., & Iovanna, J. L. (2010). Epithelial-to- mesenchymal transition in pancreatic adenocarcinoma. The Scientific World Journal, 10, 1947-1957. doi: 10.1100/tsw.2010.183.
31. Viala, E., & Pouyssegur, J. (2004). Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Annals of the New York Academy of Sciences, 1030, 208-218. doi: 10.1196/annals.1329.027.
32. Lim, J. H., Lee, E. S., You, H. J., Lee, J. W., Park, J. W., & Chun, Y. S. (2004). Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene, 23(58), 9427-9431. doi: 10.1038/sj.onc.1208003.
33. Danovi, S. A., Wong, H. H., & Lemoine, N. R. (2008). Targeted therapies for pancreatic cancer. British Medical Bulletin, 87, 97-130. doi: 10.1093/bmb/ldn027.
34. Wong, H. H., & Lemoine, N. R. (2009). Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature Reviews. Gastroenterology & Hepatology, 6(7), 412-422. doi: 10.1038/nrgastro.2009.89.
35. Lee, J., Jang, K. T., Ki, C. S., Lim, T., Park, Y. S., Lim, H. Y., et al. (2007). Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer, 109(8), 1561-1569. doi: 10.1002/cncr.22559.
36. Luo, G., Long, J., Qiu, L., Liu, C., Xu, J., & Yu, X. (2011). Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology, 11(6), 595-600. doi: 10.1159/000334465.
37. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & Depinho, R. A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Development, 20(10), 1218-1249. doi: 10.1101/gad.1415606.
38. Luttges, J., Schlehe, B., Menke, M. A., Vogel, I., Henne-Bruns, D., & Kloppel, G. (1999). The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer, 85(8), 1703-1710. doi: 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R.
39. Morris, J. P. T., Wang, S. C., & Hebrok, M. (2010). KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Reviews. Cancer, 10(10), 683-695. doi: 10.1038/nrc2899.
40. Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., & Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. American Journal of Pathology, 162(6), 1807-1815. doi: 10.1016/S0002-9440(10)64315-5.
41. Delpu, Y., Hanoun, N., Lulka, H., Sicard, F., Selves, J., Buscail, L., et al. (2011). Genetic and epigenetic alterations in pancreatic carcinogenesis. Current Genomics, 12(1), 15-24. doi: 10.2174/138920211794520132CG-12-15.
42. Matthaios, D., Zarogoulidis, P., Balgouranidou, I., Chatzaki, E., & Kakolyris, S. (2011). Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology, 81(3-4), 259-272. doi: 10.1159/000334449.
43. Steele, C. W., Oien, K. A., McKay, C. J., & Jamieson, N. B. (2011). Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), 1165-1171. doi: 10.1097/MPA.0b013e3182218ffb00006676-201111000-00002.
44. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321(5897), 1801-1806. doi: 10.1126/science.1164368.
45. Mazur, P. K., & Siveke, J. T. (2011). Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut. doi: 10.1136/gutjnl-2011-300756.
46. Skoulidis, F., Cassidy, L. D., Pisupati, V., Jonasson, J. G., Bjarnason, H., Eyfjord, J. E., et al. (2010). Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell, 18(5), 499-509. doi: 10.1016/j.ccr.2010.10.015.
47. Matsuzaki, K. (2011). Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis, 32(11), 1578-1588. doi: 10.1093/carcin/bgr172.
48. Zhao, S., Venkatasubbarao, K., Lazor, J. W., Sperry, J., Jin, C., Cao, L., et al. (2008). Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Research, 68(11), 4221-4228. doi: 10.1158/0008-5472.CAN-07-5123.
49. Bachet, J. B., Marechal, R., Demetter, P., Bonnetain, F., Couvelard, A., Svrcek, M., et al. (2012). Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Annals of Oncology. doi: 10.1093/annonc/mdr617.
50. Wagner, E. F., & Nebreda, A. R. (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews. Cancer, 9(8), 537-549. doi: 10.1038/nrc2694.
51. Ding, X. Z., & Adrian, T. E. (2001). MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochemical and Biophysical Research Communications, 282(2), 447-453. doi: 10.1006/bbrc.2001.4595 S0006-291X(01)94595-4.
52. Handra-Luca, A., Lesty, C., Hammel, P., Sauvanet, A., Rebours, V., Martin, A., et al. (2012). Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma. Pancreas, 41(3), 416-421. doi: 10.1097/MPA.0b013e318238379d.
53. del Barco Barrantes, I., & Nebreda, A. R. (2012). Roles of p38 MAPKs in invasion and metastasis. Biochemical Society Transactions, 40(1), 79-84. doi: 10.1042/BST20110676.
54. Duner, S., Lopatko Lindman, J., Ansari, D., Gundewar, C., & Andersson, R. (2010). Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology, 10(6), 673-681. doi: 10.1159/000320711.
55. Jaster, R. (2004). Molecular regulation of pancreatic stellate cell function. Molecular Cancer, 3, 26. doi: 10.1186/1476-4598-3-26.
56. Vasseur, S. T. R., Tournaire, R., & Iovanna, J. L. (2010). Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers, 2(4), 2138-2152. doi: 10.3390/cancers2042138.
57. Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews. Cancer, 8(8), 592-603. doi: 10.1038/nrc2442.
58. Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., et al. (2004). Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. Journal of Clinical Oncology, 22(13), 2610-2616. doi: 10.1200/JCO.2004.12.040 22/13/2610.
59. Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., et al. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. Journal of Clinical Oncology, 28(22), 3605-3610. doi: 10.1200/JCO.2009.25.7550.
60. Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J. L., et al. (2009). Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 27(13), 2231-2237. doi: 10.1200/JCO.2008.20.0238.
61. Graeven, U., Kremer, B., Sudhoff, T., Killing, B., Rojo, F., Weber, D., et al. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer, 94(9), 1293-1299. doi: 10.1038/sj.bjc.6603083.
62. Safran, H., Iannitti, D., Ramanathan, R., Schwartz, J. D., Steinhoff, M., Nauman, C., et al. (2004). Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation, 22(5), 706-712.
63. Fountzilas, G., Bobos, M., Kalogera-Fountzila, A., Xiros, N., Murray, S., Linardou, H., et al. (2008). Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Investigation, 26(8), 784-793. doi: 10.1080/07357900801918611.
64. Ignatiadis, M., Polyzos, A., Stathopoulos, G. P., Tselepatiotis, E., Christophylakis, C., Kalbakis, K., et al. (2006). A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology, 71(3-4), 159-163. doi: 10.1159/000106064.
65. Brell, J. M., Matin, K., Evans, T., Volkin, R. L., Kiefer, G. J., Schlesselman, J. J., et al. (2009). Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology, 76(4), 270-274. doi: 10.1159/000206141.
66. Safran, H. M. T., Bahary, N., Whiting, S., Lopez, C. D., Sun, W., Charpentier, K., Shipley, J., Anderson, E., McNulty, B., Schumacher, A., Clark, A., Vakharia, J., Kennedy, T., & Sio, T. (2011). Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study. American Journal of Clinical Oncology, 34(1), 50-52. doi: 10.1097/COC.0b013e3181d26b01.
67. Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., et al. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Journal of Clinical Oncology, 22(8), 1430-1438. doi: 10.1200/JCO.2004.10.112 JCO.2004.10.112.
68. Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., et al. (2004). A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clinical Cancer Research, 10(16), 5447-5454. doi: 10.1158/1078-0432.CCR-04-024810/16/5447.
69. Toubaji, A., Achtar, M., Provenzano, M., Herrin, V. E., Behrens, R., Hamilton, M., et al. (2008). Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunology, Immunotherapy, 57(9), 1413-1420. doi: 10.1007/s00262-008-0477-6.
70. Alberts, S. R., Schroeder, M., Erlichman, C., Steen, P. D., Foster, N. R., Moore, D. F., Jr., et al. (2004). Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. Journal of Clinical Oncology, 22(24), 4944-4950. doi: 10.1200/JCO.2004.05.034.
71. McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., et al. (2009). Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 14(4), 633-648. doi: 10.1517/14728210903232633.
72. Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., et al. (2012). Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 30(1), 382-386. doi: 10.1007/s10637-010- 9526-z.
73. El-Khoueiry, A. B., Ramanathan, R. K., Yang, D. Y., Zhang, W., Shibata, S., Wright, J. J., et al. (2012). A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investigational New Drugs, 30(3), 1175-1183. doi: 10.1007/s10637-011-9658-9.
74. Lang, S. A., Schachtschneider, P., Moser, C., Mori, A., Hackl, C., Gaumann, A., et al. (2008). Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Molecular Cancer Therapeutics, 7(11), 3509-3518. doi: 10.1158/1535-7163.MCT-08-0373.
75. Sebolt-Leopold, J. S., & Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews. Cancer, 4(12), 937-947. doi: 10.1038/nrc1503.
76. McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., et al. (2010). Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 15(2), 203-223. doi: 10.1517/14728210903282760.
77. Montagut, C., & Settleman, J. (2009). Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Letters, 283(2), 125-134. doi: 10.1016/j.canlet.2009.01.022.
78. Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23(23), 5281-5293. doi: 10.1200/JCO.2005.14.415.
79. Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology, 22(22), 4456-4462. doi: 10.1200/JCO.2004.01.185.
80. LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., et al. (2010). Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clinical Cancer Research, 16(6), 1924-1937. doi: 10.1158/1078-0432.CCR-09-1883.
81. Trujillo, J. I. (2011). MEK inhibitors: a patent review 2008-2010. Expert Opinion on Therapeutic Patents, 21(7), 1045-1069. doi: 10.1517/13543776.2011. 577068.
82. Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L., Ko, M., et al. (2009). PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics, 25(6), 519-530. doi: 10.1089/jop. 2009.0060.
83. Faivre, S., Ronot, M., Dreyer, C., Serrate, C., Hentic, O., Bouattour, M., et al. (2012). Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology, 7(2), 127-133. doi: 10.1007/s11523-012-0216-y.
84. Engelman, J. A., & Settleman, J. (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics and Development, 18(1), 73-79. doi: 10.1016/j.gde.2008.01.004.
85. Diep, C. H., Munoz, R. M., Choudhary, A., Von Hoff, D. D., & Han, H. (2011). Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clinical Cancer Research, 17(9), 2744-2756. doi: 10.1158/1078-0432.CCR-10-2214.
86. Wang, H., Daouti, S., Li, W. H., Wen, Y., Rizzo, C., Higgins, B., et al. (2011). Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Research, 71(16), 5535-5545. doi: 10.1158/0008-5472.CAN-10-4351.
87. Little, A. S., Balmanno, K., Sale, M. J., Smith, P. D., & Cook, S. J. (2012). Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochemical Society Transactions, 40(1), 73-78. doi: 10.1042/BST20110647.
88. Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439(7074), 358-362. doi: 10.1038/nature04304.
89. Jing, J., Greshock, J., Holbrook, J. D., Gilmartin, A., Zhang, X., McNeil, E., et al. (2012). Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Molecular Cancer Therapeutics, 11(3), 720-729. doi: 10.1158/1535-7163.MCT-11-0505.
90. Yip-Schneider, M. T., Lin, A., & Marshall, M. S. (2001). Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochemical and Biophysical Research Communications, 280(4), 992-997. doi: 10.1006/bbrc.2001.4243S0006-291X(01)94243- 3.
91. Yeh, J. J., Routh, E. D., Rubinas, T., Peacock, J., Martin, T. D., Shen, X. J., et al. (2009). KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Molecular Cancer Therapeutics, 8(4), 834-843. doi: 10.1158/1535-7163.MCT-08-0972.
92. Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., et al. (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics, 3, 26. doi: 10.1186/1755-8794-3-26.
93. Holt, S. V., Logie, A., Odedra, R., Heier, A., Heaton, S. P., Alferez, D., et al. (2012). The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. British Journal of Cancer, 106(5), 858-866. doi: 10.1038/bjc.2012.8 bjc20128.
94. Urick, M. E., Chung, E. J., Shield, W. P., 3rd, Gerber, N., White, A., Sowers, A., et al. (2011). Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clinical Cancer Research, 17(15), 5038-5047. doi: 10.1158/1078-0432.CCR-11-0358.
95. Zhao, Y., Shen, S., Guo, J., Chen, H., Greenblatt, D. Y., Kleeff, J., et al. (2006). Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. Journal of Surgical Research, 136(2), 325-335. doi: 10.1016/j.jss.2006.06.031.
96. Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y. M., et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research, 69(10), 4286-4293. doi: 10.1158/0008-5472.CAN-08-4765.
97. Halilovic, E., She, Q. B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., et al. (2010). PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research, 70(17), 6804-6814. doi: 10.1158/0008-5472.CAN-10-0409.
98. Chang, Q., Chen, E., & Hedley, D. W. (2009). Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biology & Therapy, 8(20), 1893-1901.
99. Chang, Q., Chapman, M. S., Miner, J. N., & Hedley, D. W. (2010). Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer, 10, 515. doi: 10.1186/1471-2407-10-515.
100. Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., et al. (2012). ERK inhibition overcomes acquired resistance to MEK inhibitors. Molecular Cancer Therapeutics, 11(5), 1143-1154. doi: 10.1158/1535-7163.MCT-11-1010.